The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis
Source : https://doi.org/10.3390/jcm11195633
Atopic dermatitis (AD) is a common inflammatory skin disease with a complex pathophysiology, intertwining immune dysregulation, epidermal barrier dysfunction, IgE sensitization, environmental factors and genetic predisposition. It has been recently identified that interleukins -4 and -13 play crucial roles in the type-2-driven inflammation that characterizes AD, contributing to its symptomatology.
Conclusion: Advances in understanding IL-4/IL-13 pathway have opened the way for the development of novel therapeutic agents that target important steps of those signaling cascades. Most importantly, monoclonal antibodies that inhibit the IL-4/IL-13 pathway have revolutionized the treatment of moderate-to-severe AD. In this context, JAK inhibitors may constitute another successful addition, as JAK-STAT signaling interferes with the IL-4/IL-13 pathway.
-
Jeremy Moss, Medical director and physician3yrA number of lines of experimental evidence over the years have suggested that IL-4 and -13 are key cytokines of the Th2 immune system and are important mediators of atopic diseases. The success of IL-4 and -13 inhibitors in ameliorating AD helps complete the circle and shows that these cytokines are truly central in the ultimate formation of atopic dermatitis in affected patients.
-
Barbara Honig3yrClearly, dupixent has revolutionized the treatment of moderate to severe AD. I am also seeing excellent results using rinvoq in AD, and I suspect that the JAK-STAT effect on the IL4/13 pathway is the reason why - inhibiting the IL4/13 pathway is the key in AD.